Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
PLoS One. 2018 Mar 20;13(3):e0194435. doi: 10.1371/journal.pone.0194435. eCollection 2018.
We searched the PubMed, EMBASE, Cochrane Library and Medline databases for eligible articles. SUVmax, MTV, and TLG on B-PET/CT, DS on I-PET/CT and DS on E-PET/CT were regarded as efficacy data. Combined hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were estimated using RevMan 5.3 software.
Nine trials with a total of 535 ENKTL patients were included. SUVmax, MTV and TLG on B-PET/CT were significantly associated with PFS with HRs of 2.78 (95%CI 1.54-5.03), 3.61 (95%CI 1.96-6.65) and 5.62 (95%CI 1.94-16.33), respectively, and with OS with HRs of 4.78 (95%CI 2.29-9.96), 3.20 (95%CI 1.55-6.60) and 7.76 (95%CI 1.79-33.58), respectively. For the DS on I-PET/CT, the HRs for PFS and OS were 5.15 (95%CI 2.71-9.80) and 5.80 (95%CI 2.28-14.73), respectively. Similarly, the DS on E-PET/CT was a significant predictor of PFS and OS with HRs of 3.65 (95%CI 2.13-6.26) and 3.32 (95%CI 1.79-6.15), respectively.
Our results suggest that SUVmax, MTV, TLG on B-PET/CT, DS on I-PET/CT and DS on E-PET/CT may be significant prognostic indicators for PFS and OS in ENKTL patients. Moreover, TLG tends to be superior to SUVmax and MTV on B-PET/CT for predicting survival of ENKTL patients. Therefore, response monitoring and prognostication assessments based on multiple PET/CT parameters should be considered in the management of ENKTL patients.
我们检索了 PubMed、EMBASE、Cochrane 图书馆和 Medline 数据库中符合条件的文章。B-PET/CT 上的 SUVmax、MTV 和 TLG、I-PET/CT 上的 DS 和 E-PET/CT 上的 DS 被视为疗效数据。使用 RevMan 5.3 软件估计无进展生存期(PFS)和总生存期(OS)的合并风险比(HR)。
纳入了 9 项共 535 例 ENKTL 患者的试验。B-PET/CT 上的 SUVmax、MTV 和 TLG 与 PFS 显著相关,HR 分别为 2.78(95%CI 1.54-5.03)、3.61(95%CI 1.96-6.65)和 5.62(95%CI 1.94-16.33),与 OS 相关的 HR 分别为 4.78(95%CI 2.29-9.96)、3.20(95%CI 1.55-6.60)和 7.76(95%CI 1.79-33.58)。对于 I-PET/CT 上的 DS,PFS 和 OS 的 HR 分别为 5.15(95%CI 2.71-9.80)和 5.80(95%CI 2.28-14.73)。同样,E-PET/CT 上的 DS 也是 PFS 和 OS 的显著预测指标,HR 分别为 3.65(95%CI 2.13-6.26)和 3.32(95%CI 1.79-6.15)。
我们的结果表明,B-PET/CT 上的 SUVmax、MTV、TLG、I-PET/CT 上的 DS 和 E-PET/CT 上的 DS 可能是 ENKTL 患者 PFS 和 OS 的重要预后指标。此外,TLG 似乎比 B-PET/CT 上的 SUVmax 和 MTV 更能预测 ENKTL 患者的生存情况。因此,在 ENKTL 患者的管理中应考虑基于多个 PET/CT 参数的反应监测和预后评估。